| 產品編號 | bs-4819R-FITC |
| 英文名稱1 | Rabbit Anti-CD45/FITC Conjugated antibody |
| 中文名稱 | FITC標記的白細胞共同抗原抗體 |
| 別 名 | B220; CD 45; CD45; cd45 antigen; ec3.1.3.48; CD45R; GP180; GP180; GP 180; L CA; LCA; L-CA; Leukocyte common antigen; LY5; Protein tyrosine phosphatase receptor type C; Protein tyrosine phosphatase receptor type c polypeptide; protein tyrosine phosphatase, receptor type, C; Receptor-type tyrosine-protein phosphatase C; PTPRC; PTPRC_HUMAN; SCID due to PTPRC deficiency; T200; T200 glycoprotein; T200 leukocyte common antigen; Human homolog of severe combined immunodeficiency due to PTPRC deficiency. |
 |
Journal
PMID
IF
Application
[IF=4.486] Jingyu Liu. et al. Low‐energy shock wave pretreatment recruit circulating endothelial progenitor cells to attenuate renal ischaemia reperfusion injury. J Cell Mol Med. 2020 Sep;24(18):10589-10603 FC ; Rat.
[IF=2.34] Hoseini et al. Fibroblast Growth Factor 1-Transfected Adipose-Derived Mesenchymal Stem Cells Promote Angiogenic Proliferation. (2017) DNA.Cell.Biol. 36:401-412 FCM ; Rat.
|
| 規格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 研究領域 | 腫瘤 細胞生物 免疫學 神經生物學 信號轉導 干細胞 轉錄調節因子 細胞表面分子 細胞類型標志物 淋巴細胞 t-淋巴細胞 b-淋巴細胞 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | Human, Mouse, (predicted: Rat, ) |
| 產品應用 | Flow-Cyt=1:50-200 ICC=1:50-200 IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 137kDa |
| 細胞定位 | 細胞膜 |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from rat CD45/B220 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產品介紹 |
background: The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP contains an extracellular domain, a single transmembrane segment and two tandem intracytoplasmic catalytic domains, and thus belongs to receptor type PTP. This gene is specifically expressed in hematopoietic cells. This PTP has been shown to be an essential regulator of T- and B-cell antigen receptor signaling. It functions through either direct interaction with components of the antigen receptor complexes, or by activating various Src family kinases required for the antigen receptor signaling. This PTP also suppresses JAK kinases, and thus functions as a regulator of cytokine receptor signaling. Four alternatively spliced transcripts variants of this gene, which encode distinct isoforms, have been reported. [provided by RefSeq, Jul 2008]. Function: Protein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN. Dephosphorylates LYN, and thereby modulates LYN activity. Subunit: Binds GANAB and PRKCSH. Interacts with SKAP1. Interacts with DPP4; the interaction is enhanced in a interleukin-12-dependent manner in activated lymphocytes. Subcellular Location: Membrane; Single-pass type I membrane protein. Membrane raft. Note=Colocalized with DPP4 in membrane rafts. Post-translational modifications: Heavily N- and O-glycosylated. DISEASE: Defects in PTPRC are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID) [MIM:608971]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development. Genetic variations in PTPRC are involved in multiple sclerosis susceptibility (MS) [MIM:126200]. MS is a neurodegenerative disorder characterized by the gradual accumulation of focal plaques of demyelination particularly in the periventricular areas of the brain. Peripheral nerves are not affected. Onset usually in third or fourth decade with intermittent progression over an extended period. The cause is still uncertain. Similarity: Belongs to the protein-tyrosine phosphatase family. Receptor class 1/6 subfamily. Contains 2 fibronectin type-III domains. Contains 2 tyrosine-protein phosphatase domains. Database links: Entrez Gene: 5788 Human Entrez Gene: 19264 Mouse Omim: 151460 Human SwissProt: P08575 Human SwissProt: P06800 Mouse Unigene: 654514 Human Unigene: 391573 Mouse Unigene: 90166 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. CD45在活化信號轉導中起到調節作用 在確定CD45為一種PTPase之前就已證實了CD45參于細胞的活化和生長調節。 抗CD45抗體可以抑制PHA或CD3交聯所介導的T細胞增殖，還可抑制NK或細胞毒性T細胞對靶細胞的殺傷，抑制經CD2、CD3以及CD8膜分子介導的信號轉導作用。 白細胞共同抗原是五種或更多的高分子量糖蛋白組成的蛋白家族，主要位于白細胞表面，包括T、B淋巴細胞、多形核白細胞、單核細胞等，而在紅細胞、血小板及非造血系統中不表達。因此是區分淋巴瘤/白血病和非造血組織腫瘤（如未分化小細胞癌、小圓細胞肉瘤）的特異性標記物。該抗體主要用于淋巴瘤和未分化小細胞癌的鑒別診斷。 |
| 產品圖片 |
Blank control: Mouse kidney.
Primary Antibody (green line): Rabbit Anti-CD45 antibody (bs-4819R-FITC)
Dilution: 1μg /10^6 cells;
Isotype Control Antibody (orange line): Rabbit IgG .
Protocol
The cells were incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. Acquisition of 20,000 events was performed.
|
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
